Vaccine development using the simian immunodeficiency virus model for AIDS

Intervirology

Volumn 45, Issue 4-6, 2002, Pages 267-274

  Norley, Stephen ^a,b   Beer, Brigitte ^b   Binninger Schinzel, Doris ^b   Vogel, Thorsten ^b   Hohn, Oliver ^a   Seibold, Erik ^a   Radke, Dörte ^a   Cosma, Corina ^b   Kurth, Reinhard ^a,b  

^a ROBERT KOCH INSTITUTE   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

Author keywords

AIDS; Lipopeptide; Live attenuated virus; Primate; Vaccine; Whole inactivated virus

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIPOPEPTIDE; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; IMMUNE RESPONSE; INFECTION PREVENTION; MONKEY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; VACCINATION; VIRUS INACTIVATION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; CERCOPITHECUS AETHIOPS; HUMANS; IMMUNIZATION, PASSIVE; MACACA MULATTA; SAIDS VACCINES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VACCINES, INACTIVATED; VACCINES, SYNTHETIC;

BACTERIA (MICROORGANISMS); CERCOPITHECUS AETHIOPS; MACACA; MACACA MULATTA; PRIMATES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0036980092     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067918     Document Type: Conference Paper

References (19)

1. Norley S, Beer B, Konig H, Jensen F, Kurth R: SIVmac vaccine studies using whole inactivated virus antigen sequentially depleted of viral proteins. J Med Primatol 1998;27:184-192.
2. Hartung S, Norley SG, Ennen J, Cichutek K, Plesker R, Kurth R: Vaccine protection against SIVmac infection by high-but not low-dose whole inactivated virus immunogen. J Acquir Immune Defic Syndr 1992;5:461-468.
3. Siegel F, Kurth R, Norley S: Neither whole inactivated virus immunogen nor passive immunoglobulin transfer protect against SIVagm infection in the African green monkey natural host. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:217-226.
4. Norley S, Beer B, Binninger-Schinzel D, Cosma C, Kurth R: Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. Virology 1996;219:195-205.
5. Beer B, Baier M, zur Megede J, Norley S, Kurth R: Vaccine effect using a live attenuated nef-deficient simian immunodeficiency virus of African green monkeys in the absence of detectable vaccine virus replication in vivo. Proc Natl Acad Sci USA 1997;94:4062-4067.
6. Vogel TU, Beer BE, zur Megede J, Ihlenfeldt HG, Jung G, Holzammer S, Watkins DI, Altman JD, Kurth R, Norley S: Induction of anti-simian immunodeficiency virus cellular and humoral immune responses in rhesus macaques by peptide immunogens: Correlation of CTL activity and reduction of cell-associated but not plasma virus load following challenge. J Gen Virol 2002;83:81-91.
7. Stott EJ, Kitchin PA, Page M, Flanagan B, Taffs LF, Chan WL, Mills KHG, Silvera P, Roders A: Anti-cell antibody in macaques. Nature 1991;353:393.
8. Kestler HW, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC: Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991;65:651-662.
9. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992;258:1938-1941.
10. Cole KS, Rowles JL, Jagerski BA, Murphey-Corb M, Unangst T, Clements JE, Robinson J, Wyand MS, Desrosiers RC, Montelaro RC: Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol 1997;71:5069-5079.
11. Binninger D, Ennen J, Bonn D, Norley SG, Kurth R: Mutational analysis of the simian immunodeficiency virus SIVmac nef gene. J Virol 1991;65:5237-5243.
12. Deres K, Schild H, Wiesmueller KH, Jung G, Rammensee HG: In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989;342:561-564.
13. Miller MD, Yamamoto H, Hughes AL, Watkins DI, Letvin NL: Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. J Immunol 1991;147:320-329.
14. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL: DNA vaccines: Protective immunization by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993;90:11478-11482.
15. Sutter G, Moss B: Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992;89:10847-10851.
16. Berglund P, Quesada-Rolander M, Putkonen P, Biberfeld G, Thorstensson R, Liljestrom P: Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses 1997;13:1487-1495.
17. Arthur LO, Pyle SW, Nara PL, Bess JW, Gonda MA, Kelliher JC, Gilden RV, Robey WG, Bolognesi DP, Gallo RC, et al: Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc Natl Acad Sci USA 1987;84:8583-8587.
18. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM: Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995;267:1820-1825.
19. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, Bronson R, Greene MF, McClure HM, Martin LN, Ruprecht RM: Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999;5:194-203.